Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GPC3 CAR T in Advanced HCC
NCT02395250Phase 1Completed
- Sponsor
- Renji Hospital
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GPC3-CART cells in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Primary endpoint: Adverse events attributed to the administration of the anti-GPC3 CAR T cells at 2 years. Started Mar 2015; status: completed.
02
Drugs
GPC3-CART cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02395250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02395250.